Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

amyotrophic lateral sclerosis

- PMLiVE

Sandoz’s application for MS biosimilar accepted by FDA

The proposed ‘first-of-a-kind’ biosimilar matched the reference medicine, Biogen’s Tysabri, in terms of efficacy, safety and immunogenicity

- PMLiVE

FDA grants Priority Review for Biogen and Eisai’s lecanemab for early Alzheimer’s disease

Lecanmab is being evaluated in the ongoing phase 3 Clarity Alzheimer's clinical trial

- PMLiVE

Biogen and Happify Health team up to create digital platform for MS patients

There are over 2.3 million people living with MS worldwide, with women being more likely to develop the condition than men

- PMLiVE

Six UK universities receive grant for research into motor neurone disease

The grant was given by the Medical Research Council and the National Institute for Health and Care Research, along with charities LifeArc, MND Association, My Name’5 Doddie Foundation and MND...

- PMLiVE

Positive CHMP opinion issued for PTC Therapeutics’ Upstaza

The treatment for AADC will be the first marketed gene therapy to be administered directly into the brain

- PMLiVE

EIT Health and Biogen announce winners of first ‘neurotechprize’

The winners, Five Lives and Neurocast, were among ten finalists working to create tech solutions for Alzheimer’s disease

- PMLiVE

Biogen and Eisai announce FDA submission for early Alzheimer’s treatment

The licence application for the treatment of mild cognitive impairment due to Alzheimer’s disease was made as part of the accelerated approval pathway programme

- PMLiVE

Biogen and MedRhythms sign deal worth over $120m for digital therapeutics for MS patients

The collaboration is focused on improving MS patients’ mobility and walking

- PMLiVE

Biogen retracts EMA application for Alzheimer’s drug Aduhelm

The application was pulled after the CHMP said the data provided was not enough to support a marketing authorisation

Biogen Idec building

Biogen shares peer-reviewed publication of Aduhelm phase 3 data

The trial data was published in The Journal of Prevention of Alzheimer’s Disease

Biogen Idec building

SMC approves Biogen’s Vumerity for patients with multiple sclerosis

The new, at-home oral treatment has been developed for adults in Scotland living with relapsing-remitting multiple sclerosis

- PMLiVE

Biogen’s Alzheimer’s treatment Aduhelm limited to clinical trial participants in the US

Biogen and The Alzheimer's Association fear that the approach will unfairly exclude patients from therapies and create further healthcare inequities

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links